FORTUNE and Great Place to Work Name Second Genome a "Top 10 Best Workplace in Biopharma"
April 10, 2019, South San Francisco, CA
Second Genome Expands Development of CNS Platform to Validate Microbial Products as Therapeutics for Autism Spectrum Disorder
March 26, 2019, South San Francisco
Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)
January 23, 2019, South San Francisco
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
September 26, 2018, South San Francisco, CA
Second Genome Certified as Great Place to Work®
July 31, 2018, South San Francisco, July 30, 2018
Second Genome Appoints Anupama S. Hoey as Chief Business Officer
July 23, 2018, South San Francisco, July 23, 2018
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
April 9, 2018, SOUTH SAN FRANCISCO, Calif.
Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer
March 5, 2018, South San Francisco, CA March 5, 2018